Tag: Panxora

Panxora Digital Ventures Launches Innovative Hybrid Seed Funding Solution For Blockchain and Cryptocurrency Token Sales

boss

Panxora Digital Ventures has launched its hybrid seed funding solution to revive the sluggish capital market for emerging Blockchain token projects. The companies’ hybrid model creates a two-stage fundraising process that bridges the gap between seed investors’ interests and token founders’ needs to produce better results. Gavin Smith, CEO at Panxora, said: “Our hybrid offering provides blockchain project founders and investors alike with a professional solution to the challenges they face. Investors see our hybrid methodology not only as a structure that will improve the performance of projects but a…

Panxora Opens To Open Up AI-Driven DeFi Hedge Fund For Investors – Blockchain News, Opinion, TV and Jobs

boss

Cayman Islands-based The Panxora Group is kicking off a new quantitative hedge fund on Monday, November 2, 2020 — designed to generate profits from the rapidly growing Decentralised Finance or (DeFi) token market. Marcie Terman, COO at Panxora stated: “This fund is meant for people that want exposure to DeFi but lack the resources to research this very specialist market themselves. These person-to-person transactions could have a profound impact on global financial services – bringing real-world assets onto the blockchain and facilitating the transfer of trillions of dollars of assets…

Panxora Backs Clintex To Raise $7 Million USD And Provide Faster Access To Medicines – Blockchain News, Opinion, TV and Jobs

boss

Digital asset treasury management service Panxora says it will support ClinTex, a pharmaceuticals industry solutions provider, in raising and managing $7 million USD for a blockchain-powered clinical trials solution to accelerate access to medicines for patients. Panxora will provide a management framework, determining when capital raised is released into the project, which will enable ClinTex to strategically grow its business. Brendan Mannion, ClinTex’s co-founder, said: “Our main priority has always been to meet patients’ needs. Recent circumstances have exposed the pharmaceutical industry’s flaws and reluctance to share data. However, with…